Modulation of the Fas signaling pathway by IFN-γ in therapy of colon cancer: Phase I trial and correlative studies of IFN-γ, 5-fluorouracil, and leucovorin

Clinical Cancer Research

Volumn 8, Issue 8, 2002, Pages 2488-2498

  Schwartzberg, Lee S ^a   Petak, Istvan ^b   Stewart, Clinton ^b   Turner, P Kellie ^b   Ashley, Jeri ^a   Tillman, David M ^b   Douglas, Leslie ^b   Tan, Ming ^b   Billups, Catherine ^b   Mihalik, Rudolf ^c   Weir, Alva ^a   Tauer, Kurt ^a   Shope, Steve ^a   Haughton, Janet A ^b  

^a West Clinic   (United States)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^c SEMMELWEIS UNIVERSITY OF MEDICINE   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

CD15 ANTIGEN; FAS ANTIGEN; FLUOROURACIL; FOLINIC ACID; GAMMA INTERFERON; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIMETABOLITE;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CLINICAL TRIAL; COLON CANCER; COLORECTAL CARCINOMA; DNA DAMAGE; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CYTOTOXICITY; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; STOMATITIS; TREATMENT OUTCOME; BIOLOGICAL MODEL; BIOSYNTHESIS; CELL CULTURE; CELL SEPARATION; COLORECTAL TUMOR; FLOW CYTOMETRY; FOLLOW UP; METABOLISM; MIDDLE AGED; TIME; UPREGULATION;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD15; ANTIGENS, CD95; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL SEPARATION; COLORECTAL NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FLOW CYTOMETRY; FLUOROURACIL; FOLLOW-UP STUDIES; HUMAN; INTERFERON TYPE II; LEUCOVORIN; MALE; MIDDLE AGE; MODELS, BIOLOGICAL; SIGNAL TRANSDUCTION; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.; TIME FACTORS; TUMOR CELLS, CULTURED; UP-REGULATION; HUMANS; MIDDLE AGED;

EID: 0036023429     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. A randomized trial of fluorouracil and folinic acid in patients with metastatic colorectal carcinoma
2. Prospective randomized comparison of fluorouracil and high-dose continuous infusion leucovorin calcium for the treatment of advanced measurable colorectal cancer in patients previously unexposed to chemotherapy
3. A prospective randomized trial of 5-fluorouracil versus 5-fluorouracil and high-dose leucovorin versus 5-fluorouracil and methotrexate in previously untreated patients with advanced colorectal carcinoma
4. The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: A prospective randomized phase III trial
5. Biochemical modulation of fluorouracil: Evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma
6. Irinotecan plus fluorouracil for metastatic colorectal cancer
7. Irinotecan combined with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicentre randomised trial
8. The ratio of dATP/dTTP influences the commitment of human colon carcinoma cells to thymineless death
9. A Fas-dependent component in 5-fluorouracil/leucovorin-induced cytotoxicity in colon carcinoma cells
10. Factors that influence the therapeutic activity of 5-fluorouracil-[6RS]leucovorin combinations in colon adenocarcinoma xenografts
11. Mechanism of induction of gastrointestinal toxicity in the mouse by 5-fluorouracil, 5-fluorouridine and 5-fluoro-2′-deoxyuridine
12. Inhibition by uridine but not thymidine of p53-dependent intestinal apoptosis initiated by 5-fluorouracil: Evidence for the involvement of RNA perturbation
13. Fas involvement in Ca(2+)-independent T cell-mediated cytotoxicity
14. Fas and Fas ligand in embryos and adult mice: Ligand expression in several immune-privileged tissues and coexpression in adult tissues characterized by apoptotic cell turnover
15. Expression of APO-1 (CD95), a member of the NGF/TNF receptor superfamily, in normal and neoplastic colon epithelium
16. Constitutive and induced expression of APO-1, a new member of the nerve growth factor/tumor necrosis factor receptor superfamily, in normal and neoplastic cells
17. A novel AP-1 element in the CD95 ligand promoter is required for induction of apoptosis in hepatocellular carcinoma cells upon treatment with anticancer drugs
18. The chemotherapeutic drug 5-fluorouracil induces apoptosis in mouse thymocytes in vivo via activation of the CD95(APO-1/Fas) system
19. Thymineless death in colon carcinoma cells is mediated via Fas signaling
20. Expression of genes that regulate Fas signalling and Fas-mediated apoptosis in colon carcinoma cells
21. A genetic model for colorectal tumorigenesis
22. P53 dependence of Fas induction and acute apoptosis in response to 5-fluorouracil-leucovorin in human colon carcinoma cell lines
23. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer
24. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer
25. Fas-dependent and -independent mechanisms of cell death following DNA damage in human colon carcinoma cells
26. A pilot study of interferon alfa-2a in combination with fluorouracil plus high-dose leucovorin in metastatic gastrointestinal carcinoma
27. 5-Fluorouracil and recombinant α2a-interferon: An active regimen against colorectal carcinoma
28. Treatment of advanced colorectal cancer with 5-fluorouracil and interferon-α: An overview of clinical trials
29. Evidence that types I and II interferons have different receptors